Short answer
OrfoLean is sold as a 30-capsule dietary supplement with three items in its facts panel. According to the distributor, the ingredient listed as ORFOLEAN™ is orforglipron. The label does not state this, and we have not seen an independent analysis confirming its identity, amount or purity. Orforglipron is the active substance of a prescription medicine. Its trial results describe that medicine, taken under medical supervision and in amounts other than the 8 mg printed on this label.
This is a label analysis. We have not used this product and have not had its contents tested. Label read on 15 November 2026; regulatory status checked on 16 November 2026.
Label breakdown
The label we read is that of Smart Brothers OrfoLean 30 caps. The front of the bottle reads “NEXT-GENERATION FAT BURNER”, “FAT BURN | CONTROL | METABOLISM” and “DIETARY SUPPLEMENT”. The facts panel gives one capsule per serving, 30 servings and three items.
| Ingredient (label spelling) | Per capsule | What the label says about it | Evidence |
|---|---|---|---|
| AFFRON® | 30 mg | Name only | Human trials, on mood and sleep |
| ORFOLEAN™ | 8 mg | Trade name only | Not identified on the label. The distributor states it is orforglipron; trials of the prescription medicine do not describe this capsule (see below) |
| SLU-PP-322 | 250 mcg | Name only | None under this spelling. SLU-PP-332: animal and cell studies only |
The panel carries this warning:
“This product is for users aged 18 and over. Please consult a doctor prior to use if you have or are at risk of prostate disease, heart disease or any medical condition. Do not consume with alcohol or any stimulants. Discontinue use immediately if you experience rapid heart rate, dizziness, vomiting or similar symptoms.”
The three ingredients
Affron
Affron is a branded extract of saffron (Crocus sativus L.) stigmas from Pharmactive Biotech Products. The European Food Safety Authority (EFSA) describes it as an aqueous extract with a combined crocin and safranal content of typically 3.5% to 3.9%. Its human trials mainly concern mood and sleep. Two of them tested 28 mg a day: over 4 weeks in 128 adults with low mood, where it improved mood scores against placebo and 22 mg a day did not, and over 12 weeks in 202 adults with depressive symptoms. In 2021 EFSA assessed a mood claim for Affron and found the evidence insufficient to establish cause and effect. PubMed (16 November 2026) lists no human trial of Affron with body weight or fat loss as an outcome.
The ingredient named “ORFOLEAN™”
The label gives a trade name and a quantity, 8 mg. According to the distributor, the ingredient listed as ORFOLEAN™ is orforglipron. The label does not state this, and we have not seen an independent analysis confirming its identity, amount or purity. What is known about orforglipron itself is set out in the next section.
“SLU-PP-322”
This is the label’s spelling, and PubMed returns no records for it. The compound known from the literature is SLU-PP-332, a synthetic agonist of the oestrogen-related receptors (ERRs), first reported in 2022 preprints and in a peer-reviewed journal in 2023. In mice it increased exercise endurance and, in models of obesity, reduced fat mass. PubMed lists 12 records for SLU-PP-332 and the related SLU-PP-915, none a human trial, and ClinicalTrials.gov lists no registered study (checked 16 November 2026). We do not know whether the label’s spelling is a typo. More background is in our SLU-PP-332 article.
What orforglipron is
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly and marketed as Foundayo.
Its regulatory status:
- United States: approved by the FDA on 1 April 2026 as a prescription tablet for weight reduction and maintenance in adults with obesity, or with overweight and a weight-related condition.
- United Kingdom: authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes, prescription-only.
- European Union: the EMA’s human medicines committee adopted a positive opinion on 15 October 2026. With no European Commission decision published, there is no EU marketing authorisation yet.
| Trial | Population | Duration | Arms | Primary result: mean change in body weight | Source |
|---|---|---|---|---|---|
| ATTAIN-1 | 3,127 adults with obesity or overweight, without diabetes | 72 weeks | 6 mg, 12 mg, 36 mg, placebo | −7.5%, −8.4%, −11.2%; placebo −2.1% | Wharton et al., N Engl J Med, 2025 |
| ATTAIN-2 | 1,613 adults with BMI ≥27 and type 2 diabetes | 72 weeks | 6 mg, 12 mg, 36 mg, placebo | −5.1%, −7.0%, −9.6%; placebo −2.5% | Horn et al., Lancet, 2025 |
Both trials were funded by Eli Lilly. Figures use the treatment-regimen estimand, the primary analysis, which counts every randomised participant whether or not they stayed on treatment. The FDA label presents the same arms as “equivalent dosages” of the marketed tablet: 5.5 mg, 9 mg and 17.2 mg.
In the FDA label’s pooled data from both trials (3,155 people on orforglipron, 1,576 on placebo), gastrointestinal reactions affected 60% to 69% on orforglipron and 37% on placebo: nausea 26% to 35% (placebo 10%), constipation 20% to 27% (9%), diarrhoea 21% to 25% (11%), vomiting 13% to 24% (4%). Adverse events led 5.3% to 10.3% of orforglipron participants to stop treatment in ATTAIN-1 (placebo 2.7%) and 6.1% to 9.9% in ATTAIN-2 (placebo 4.1%). ATTAIN-2 reported ten deaths, six on orforglipron (983 participants) and four on placebo (630). Investigators judged eight unrelated to treatment; the exceptions were one placebo case and one in the 12 mg arm, for which no treatment-related association was reported.
The US label carries a boxed warning on the risk of thyroid C-cell tumours and contraindicates the medicine in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Its warnings include acute pancreatitis, acute kidney injury, hypoglycaemia and gallbladder disease.
What the trial data do and do not cover
- Identity. That the capsule contains orforglipron is the distributor’s statement. The label does not say so, and no independent test known to us has confirmed identity, amount or purity.
- Quantity. The label lists 8 mg. The trial arms were 6 mg, 12 mg and 36 mg of an investigational formulation; the marketed tablets range from 0.8 mg to 17.2 mg, with no 8 mg strength. This compares printed numbers only.
- Other ingredients. The capsule lists two more ingredients that were not part of the orforglipron trials. One of them, under the spelling SLU-PP-332, has no human data.
- Trial conditions. Participants were screened before enrolment and followed by study physicians for 72 weeks.
- Oversight. Foundayo went through regulatory assessment, is dispensed on prescription and stays under review after authorisation. Dietary supplements have no pre-market approval: the FDA “does not have the authority to approve dietary supplements before they are marketed”.
Legal and anti-doping status
Status checked on 16 November 2026.
- Orforglipron in the UK: prescription-only. The MHRA: GLP-1 medicines “can only be obtained from a registered pharmacy, with a prescription from a doctor”.
- Orforglipron in the EU: not yet authorised. EMA: “All medicines must be authorised before they can be marketed and made available to patients.”
- This product: it is labelled as a dietary supplement and, according to the distributor, contains the active substance of a prescription medicine. We found no regulator statement naming this product (searched 16 November 2026). Whether it can be sold in a given country is for that country’s regulator to decide.
- SLU-PP-332 and WADA: the 2026 Prohibited List does not name it. Its class S0 prohibits at all times any pharmacological substance not covered by other sections and “with no current approval by any governmental regulatory health authority for human therapeutic use”; we found no such approval for SLU-PP-332. The 2027 List, in force from 1 January 2027, names “SLU-PP-332, SLU-PP-915 and related substances” in class S4.4.1 (metabolic modulators). The label’s spelling, SLU-PP-322, appears in neither edition.
- GLP-1 receptor agonists and WADA: neither edition mentions GLP-1 receptor agonists or orforglipron. WADA’s separate 2027 Monitoring Program, for substances not on the List, includes “GLP-1 Agonists: In and Out-of-Competition: Semaglutide and tirzepatide”.
- Drug-tested athletes: one listed ingredient, SLU-PP-322, differs by one digit from SLU-PP-332, which the 2027 List names, and the contents have not been independently verified. Not for drug-tested athletes.
This article replaces an earlier version, which presented orforglipron trial results as results for the product.
Sources
- Product label: Smart Brothers OrfoLean 30 caps, front panel and “Supplements Facts” panel. Read on 15 November 2026.
- Wharton S, Aronne LJ, Stefanski A, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med, 393(18), 1796–1806. PMID: 40960239.
- Horn DB, Ryan DH, Kis SG, et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet, 406(10522), 2927–2944. PMID: 41275875.
- US Food and Drug Administration. Drugs@FDA: NDA 220934, Foundayo (orforglipron) tablets. Original approval 1 April 2026. Accessed 16 November 2026.
- Eli Lilly and Company. Foundayo (orforglipron) tablets: prescribing information. DailyMed, label version 10, effective 29 July 2026. Accessed 16 November 2026.
- Medicines and Healthcare products Regulatory Agency (2026). UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. Press release, 10 August 2026. Accessed 16 November 2026.
- European Medicines Agency. Foundayo (orforglipron): CHMP opinion, EMEA/H/C/006632. Opinion adopted 15 October 2026. Accessed 16 November 2026.
- European Medicines Agency. Authorisation of medicines. Accessed 16 November 2026.
- US Food and Drug Administration. Questions and Answers on Dietary Supplements. Content current as of 27 August 2026. Accessed 16 November 2026.
- Kell G, Rao A, Beccaria G, et al. (2017). affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med, 33, 58–64. PMID: 28735826.
- Lopresti AL, Smith SJ, Marx W, et al. (2025). An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Nutr, 155(7), 2300–2311. PMID: 40414301.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (2021). Affron® and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J, 19(7), 6669. PMID: 34249157.
- Billon C, Sitaula S, Banerjee S, et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol, 18(4), 756–771. PMID: 36988910.
- Billon C, Schoepke E, Avdagic A, et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther, 388(2), 232–240. PMID: 37739806.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.
- World Anti-Doping Agency. The 2027 Monitoring Program. Accessed 16 November 2026.
